| 0.0282 -0.013 (-32.05%) | 10-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.01 | 1-year : | 0.02 |
| Resists | First : | 0.01 | Second : | 0.02 |
| Pivot price | 0 |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0 |
MA(20) : | 0 |
| MA(100) : | 0.14 |
MA(250) : | 0.66 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21.2 |
D(3) : | 17.5 |
| RSI | RSI(14): 33.7 |
|||
| 52-week | High : | 1.45 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RVLP ] has closed above bottom band by 28.7%. Bollinger Bands are 97.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Tue, 13 Feb 2024
RVL Pharmaceuticals Ordered to Liquidate by Irish High Court - TipRanks
Thu, 12 Oct 2023
RVLP - RVL Pharmaceuticals plc Latest Stock News & Market Updates - StockTitan
Thu, 12 Oct 2023
RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries - GlobeNewswire
Mon, 10 Apr 2023
RVLP: Bright-Eyed and Bushy-Tailed - Zacks Small Cap Research
Mon, 03 Apr 2023
RVL Pharmaceuticals Announces that Upneeq® Wins “Best Eye - GlobeNewswire
Thu, 04 Aug 2022
RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 111 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 27 (%) |
| Held by Institutions | 49 (%) |
| Shares Short | 3,280 (K) |
| Shares Short P.Month | 1,360 (K) |
| EPS | -0.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | -185 % |
| Operating Margin | -98.4 % |
| Return on Assets (ttm) | -23.7 % |
| Return on Equity (ttm) | -182.5 % |
| Qtrly Rev. Growth | -2.3 % |
| Gross Profit (p.s.) | 0.38 |
| Sales Per Share | 0.33 |
| EBITDA (p.s.) | -0.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|